Revolution Medicines, Inc. Warrant (RVMDW) Stock Price & Analysis

Revolution Medicines, Inc. Warrant (RVMDW) Healthcare & Pipeline Overview

Revolution Medicines, Inc. is a clinical-stage biotechnology firm specializing in precision oncology with a focus on RAS-addicted cancers. Their pipeline of RAS(ON) and companion inhibitors targets unmet needs in cancer treatment, positioning them within a competitive and rapidly evolving biotech landscape.

What Is the Investment Thesis for RVMDW?

Revolution Medicines presents a high-risk, high-reward investment opportunity within the precision oncology space. The company's focus on RAS-addicted cancers, a historically difficult-to-drug target, offers significant potential upside if its clinical programs are successful. Key value drivers include the advancement of its RAS(ON) inhibitors and RAS companion inhibitors through clinical trials, particularly RMC-4630 in Phase 2. Upcoming data readouts from these trials will be critical catalysts. However, the company faces significant risks, including the inherent challenges of drug development, potential clinical trial failures, and competition from other companies targeting the RAS pathway. With a market cap of $0.32 billion and a negative P/E ratio of -15.94, the company's valuation is largely dependent on the success of its pipeline.

Based on FMP financials and quantitative analysis

RVMDW Key Highlights

Revolution Medicines is a clinical-stage company focused on precision oncology, specifically targeting RAS-addicted cancers.

• The company's pipeline includes both RAS(ON) inhibitors and RAS companion inhibitors, with multiple programs in Phase 1 and Phase 2 clinical trials.
• RMC-4630, a RAS companion inhibitor, is currently in Phase 2 clinical trial, representing a near-term value driver.
• The company's market capitalization is $0.32 billion, reflecting the early stage of its clinical programs and associated risks.
• Revolution Medicines has 616 employees, indicating a significant investment in research and development infrastructure.

Who Are RVMDW's Competitors?

RVMDW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RVMDW's Key Strengths?

Proprietary technology targeting RAS-addicted cancers.

• Diverse pipeline of RAS(ON) and companion inhibitors.
• Experienced management team with expertise in drug development.
• Strong intellectual property position.

What Are RVMDW's Weaknesses?

Clinical-stage company with no approved products.

• High cash burn rate due to extensive R&D activities.
• Reliance on successful clinical trial outcomes.
• Limited commercialization capabilities.

What Are the Key Risks for RVMDW?

Negative return on equity (-96.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $36.7M recently.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of drug candidates.
• Competition from other companies developing RAS-targeted therapies.
• High cash burn rate and need for additional financing.
• Dependence on key personnel and intellectual property.

What Are RVMDW's Competitive Advantages?

• Proprietary RAS(ON) inhibitor technology.
• Extensive pipeline of RAS-targeted therapies.
• Strong intellectual property portfolio.
• Expertise in RAS biology and drug discovery.

What Does RVMDW Do?

Revolution Medicines, Inc., founded in 2014 and headquartered in Redwood City, California, is a clinical-stage precision oncology company dedicated to discovering and developing novel targeted therapies for RAS-addicted cancers. The company's mission is to transform cancer treatment by creating innovative medicines that specifically target the RAS signaling pathway, a critical driver of many human cancers. Revolution Medicines' research and development efforts are centered on two main classes of compounds: RAS(ON) inhibitors and RAS companion inhibitors. The company's RAS(ON) inhibitors are designed to directly inhibit the activity of RAS proteins, which are often mutated or overexpressed in cancer cells. These inhibitors are being developed as monotherapies and in combination with other RAS(ON) inhibitors, RAS companion inhibitors, or other therapeutic agents. Key RAS(ON) inhibitor programs include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), all of which are currently in Phase 1 clinical trials. Other development candidates include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), along with programs targeting G12R and other RAS variants. Revolution Medicines' RAS companion inhibitors are designed to enhance the effectiveness of RAS(ON) inhibitors or other cancer therapies. These inhibitors target proteins that interact with or regulate the RAS signaling pathway. The company's RAS companion inhibitor programs include RMC-4630, which is in Phase 2 clinical trial, and RMC-5552, which is in Phase 1 clinical trial. Revolution Medicines is committed to advancing its pipeline of innovative cancer therapies through clinical development and ultimately bringing them to patients in need.

What Products and Services Does RVMDW Offer?

• Develop novel targeted therapies for RAS-addicted cancers.
• Research and develop RAS(ON) inhibitors designed for monotherapy or combination therapy.
• Create RAS companion inhibitors for combination treatment strategies.
• Conduct Phase 1 and Phase 2 clinical trials for various drug candidates.
• Focus on inhibiting difficult-to-drug RAS mutations like G12V, Q61H, G13C, and G12R.
• Develop therapies to treat cancers driven by mutations in the RAS signaling pathway.

How Does RVMDW Make Money?

• Develops and patents novel cancer therapies.
• Out-licenses or co-develops therapies with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties on partnered drugs.
• Funds research and development through venture capital and public offerings.

What Industry Does RVMDW Operate In?

Revolution Medicines operates in the competitive biotechnology industry, specifically within the precision oncology market. This market is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The company's focus on RAS-addicted cancers aligns with a growing understanding of the genetic drivers of cancer and the potential for targeted therapies. The competitive landscape includes companies such as Amgen and Mirati Therapeutics, which have already brought KRAS G12C inhibitors to market. Revolution Medicines aims to differentiate itself through its pipeline of RAS(ON) inhibitors and RAS companion inhibitors targeting a broader range of RAS mutations.

Who Are RVMDW's Key Customers?

• Cancer patients with RAS mutations.
• Oncologists and other healthcare providers.
• Pharmaceutical companies seeking to license or co-develop cancer therapies.

60 transactions · 0 purchases, 48 sales, 12 other transactions · 9 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 29, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Wall Street analysts project Revolution Medicines, Inc. Warrant revenue of about $191.2M for fiscal 2026, with EPS near $-9.65. The estimate reflects 22 contributing analysts.

Revolution Medicines, Inc. Warrant's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.12 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Revolution Medicines, Inc. Warrant stands at -96.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.1%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Revolution Medicines, Inc. Warrant operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Mark A. Goldsmith. RVMDW has traded publicly since 2020.

RVMDW Financials

RVMDW Latest News

RVMDW Analyst Consensus

RVMDW MoonshotScore

Common Questions About RVMDW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources